TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04585750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: First-in-class, oral, small molecule p53 reactivator selective for the p53 Y220C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
Study: NCT04376593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-αvβ6-BP
Description: Subjects will be injected once per imaging session (a maximum of 3 imaging sessions) with up to 10 mCi (±20%) of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 secs).
Study: NCT04053816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium
Description: The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol.
Study: NCT05507749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryoballoon ablation
Description: Cryoballoon ablation for the treatment of atrial fibrillation
Study: NCT04555759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-minute walk test
Description: The patients will do a 2-minute walk test, using their walking aids or braces
Study: NCT03292237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition
Description: Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
Study: NCT04790500

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobilization technique
Description: Mobilization of sacroiliac joint which will increase the range of motion and reduction in pain and improvement in functional limitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: Muscle energy technique it is known as active muscular relaxation technique. It helps in lengthening the shorten muscle and increasing range of restricted muscles
Study: NCT02612246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 single ascending doses
Description: single dose, oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single dose
Description: single dose, oral solution, matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 multiple ascending doses
Description: multiple doses, daily for 14 days, oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple doses
Description: multiple doses, daily for 14 days, oral solution
Study: NCT00754884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmon calcitonin
Description: daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal saline solution plus glycerol
Description: daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
Study: NCT03721250

Intervention type: OTHER
Intervention: epidural
Description: thoracic epidural analgesia
Study: NCT04232852

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic mix
Description: The probiotic mix will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive an identical capsule of maltodextrin.
Study: NCT05507749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implantable loop recorder insertion
Description: The device called a implantable loop recorder, is placed just under the skin of one's chest during a minor surgery.
Study: NCT00432094

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
Study: NCT01763021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-32765
Description: PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11
Study: NCT02433964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grupo LED
Study: NCT01763021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.
Study: NCT02178501

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA
Description: comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 PUFA
Description: comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo
Study: NCT02473003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity exercise
Description: high intensity exercise 80-90%
Study: NCT01606059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW-0919
Description: Dosage form: Extended release tablet Dosage: 1 tablet
Study: NCT02549794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT angiography with high concentration contrast agent
Description: Standard concentration of iodine contrast agent for CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT angiography with low concentration contrast agent (320)
Description: Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT angiography with low concentration contrast agent (270)
Description: Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
Study: NCT01051713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Supported
Description: Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard
Description: Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits.
Study: NCT01638650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
Description: in accordance with current clinical HIV treatment guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg bid orally, Days 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir [Invirase]
Description: 500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14
Study: NCT04557176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRP, point-of-care assay
Description: CRP is a non-specific marker of inflammation whose levels rise in the setting of interleukin 6 (IL-6)-mediated inflammation, such as active TB. In clinical settings, CRP is used to identify patients with systemic inflammation from infection or non-infectious cases. In settings with high TB prevalence, the investigators hypothesize that CRP can be used to accurately screen individuals for active TB (i.e., distinguish individuals with high likelihood of having active TB from those individuals unlikely to have active TB).
Study: NCT02433964

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ledterapia off + price
Study: NCT00077584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg
Description: Oral tablets containing 62.5 mg of bosentan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg
Description: Oral tablets containing 125 mg of bosentan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
Study: NCT00507546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: 8 mg nightly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Nightly 8mg of placebo (same appearance as ramelteon)
Study: NCT03338842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distractor and Lower limb VR
Description: In the first phase (A), subjects will receive the Distraction VR treatment during 5, 6, or 7 one-hour-long sessions occurring twice weekly. After the A phase, the remaining sessions (B phase) will consist of Lower-Limb VR treatment. This number includes a mean of 6 (range 5-7) phase A sessions and mean of 11 (range 10-12) phase B sessions.
Study: NCT03201354

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Filtration surgery with Ex-PRESS
Description: Filtration surgery with Ex-PRESS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non penetrating deep sclerectomy
Description: Non penetrating deep sclerectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract extraction
Description: Cataract surgery and IOL implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract extraction
Description: Cataract surgery and IOL implantation
Study: NCT02141321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study: NCT01866969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02473003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity exercise
Description: high intensity exercise 80-90%

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low/medium intensity exercise
Description: low/medium intensity exercise 40-50%

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low/medium intensity exercise
Description: low/medium intensity exercise 40-50%

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral medicine strategies
Description: Motivational and self-regulatory behavioral medicine support strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral medicine strategies
Description: Motivational and self-regulatory behavioral medicine support strategies
Study: NCT02513784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
Study: NCT03280342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR-TPM (Topamax)
Description: XR-TPM (Trokendi XR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR-TPM (Topamax)
Description: XR-TPM (Trokendi XR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XR-TPM (Trokendi XR)
Description: XR-TPM (Trokendi XR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XR-TPM (Trokendi XR)
Description: XR-TPM (Trokendi XR)
Study: NCT05038748

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5

Intervention type: OTHER
Intervention: ASD diagnosis
Description: Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
Study: NCT02495740

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Commuting to work
Description: Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commuting to work
Description: Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week
Study: NCT01726413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 17356
Study: NCT04476472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod Horizon™ Automated Glucose Control System
Description: The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery.
Study: NCT04225403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based motivational interviewing for smoking cessation
Description: The motivational brief intervention is known by the acronym 5 R and lasts about 5-10 minutes. It is an approach based on the principles of motivational interviewing and develops the intervention in five short steps:~* Relevance. Help patients identify why personal reasons may be relevant to quitting smoking.~* Risks. Help identify what negative consequences tobacco use has.~* Rewards. Help identify potential benefits of quitting smoking.~* Resistors. Help patients identify barriers to smoking cessation, which can often include fear of withdrawal symptoms, failure, wainweight, face social situations, etc.~* Repeat. Repeat the intervention at 3 months if you do not advance at the stage of change.
Study: NCT02141321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01726413

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Study: NCT05689138

Intervention type: OTHER
Intervention: Oral and Fecal Sample Collection
Description: No interventions

Intervention type: OTHER
Intervention: Oral and Fecal Sample Collection
Description: No interventions
Study: NCT01430390

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Genetically Modified T cells
Description: Following completion of the chemotherapy, genetically modified T cells will be given intravenously at one of 3 dose levels. After the infusion patients will be monitored clinically and with serial blood and marrow evaluations to assess toxicity, therapeutic effects, and the in-vivo survival of the genetically modified T-cells. A fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose allowing for multiple infusions and potential for multiple patient treatments per cell line generated will be used for all patients on this trial. Cohorts will be determined separately but cohort 3 will not begin to accrue until cohort 2 has treated three (3) patients without a DLT. Each patient is eligible for up to three (3) infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-based chemotherapy
Description: Cyclophosphamide-based chemotherapy regimen will be the preferred conditioning chemotherapy prior to CAR T cell infusion for patients with CD19+ malignancy in cohort 1. Recommended chemotherapy regimen consists of single agent Cyclophosphamide at a dose of 3000 mg/m2/dose IV over 1 hour or 1500mg/m2/dose x 2 doses given daily over 1 hour given for 2 days (patients may received reduced dose of cyclophosphamide based on the clinical status of the patient at discretion of the treating physician and with written approval by the MSKCC PI of this study). Alternative cyclophosphamide or non-cyclophosphamide-based regimens based on the clinical status of the patient, disease burden, and likely-hood of response may be used at the discretion of the treating physician with written approval by MSKCC PI of the study. Conditioning chemotherapy will not be given prior to infusions # 2 and #3.
Study: NCT04518501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide Tablet +Fuzuloparib Capsules
Description: Arsenic trioxide Tablet : 0.27\*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po
Study: NCT03705234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Study: NCT04128709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urodynamics Testing
Description: The non-invasive device connects to the end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device the patient presses a single button in order to obtain a pressure measurement which is recorded and stored in the device along with the time and date. The measurement(s) can later be transmitted wirelessly to a smart phone that contains an app for the device.
Study: NCT04261777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrotran® (Ferumoxtran-10)
Description: Ferrotran® in a dose of 0.13 mL/kg body weight of the reconstituted freeze-dried preparation (i.e. 2.6 mgFe/kg body weight). The recommended dose should be diluted in 100 mL of NaCl 9 mg/mL (0.9%) solution for injection/infusion prior to administration via the infusion filter as a slow intravenous infusion over 30 minutes (at a maximum rate of 4 mL/min).~Ferrotran® will be administered once to each patient. Histologically confirmed diagnosis and pre-operative staging are performed prior to the study as part of standard care. Surgery (RP with ePLND) and sampling of tissue specimens is performed after the Ferrotran®-enhanced MRI as part of standard care.
Study: NCT01604317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation-torso plastic bag
Description: Infant's extremities and torso will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation-partial-head plastic bag
Description: Infant's torso, extremities, and portion of the head (face will be exposed) will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
Study: NCT01813383

Intervention type: OTHER
Intervention: There is not any intervention

Intervention type: OTHER
Intervention: There is not any intervention
Study: NCT01210820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFS™ Femtosecond Laser System
Description: intrastromal arcuate cuts made with iFS™ femtosecond laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFS™ Femtosecond Laser System
Description: intrastromal arcuate cuts made with iFS™ femtosecond laser
Study: NCT02210806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A006 DPI
Description: Single dose 110 mcg, 1 inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A006 DPI
Description: Single dose 220 mcg, 1 inhalation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DPI
Description: Placebo, 1 inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil® MDI
Description: Single dose 90 mcg, 1 inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil® MDI
Description: Single dose 90 mcg, 2 inhalations